{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14(6)"],"submitter":["Chandola R"],"pubmed_abstract":["We report the case of a 59-year-old patient with Heartware (Framingham, MA, USA) biventricular assist device (BIVAD) implantation who had long-term sustained ventricular fibrillation and was managed on low-molecular-weight heparin for up to two years without any adverse events. The successful outcome in this case provides a clue that the long-term management of Heartware BIVADs with low-molecular-weight heparins could be a viable option even in patients with underlying malignant arrhythmias. <Learning objective: Long-term management of Heartware biventricular assist devices (BIVADs) using low-molecular-weight heparin is possible. This treatment strategy can serve as an alternative to oral anticoagulants in a select group of patients. This case report also suggests that BIVADs can potential"],"journal":["Journal of cardiology cases"],"pagination":["171-173"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6283705"],"repository":["biostudies-literature"],"pubmed_title":["Long-term use of low-molecular-weight heparin in a patient with Heartware BIVAD (HVAD) with underlying sustained ventricular fibrillation."],"pmcid":["PMC6283705"],"pubmed_authors":["Chandola R","Buchholz H","Macarthur R"],"additional_accession":[]},"is_claimable":false,"name":"Long-term use of low-molecular-weight heparin in a patient with Heartware BIVAD (HVAD) with underlying sustained ventricular fibrillation.","description":"We report the case of a 59-year-old patient with Heartware (Framingham, MA, USA) biventricular assist device (BIVAD) implantation who had long-term sustained ventricular fibrillation and was managed on low-molecular-weight heparin for up to two years without any adverse events. The successful outcome in this case provides a clue that the long-term management of Heartware BIVADs with low-molecular-weight heparins could be a viable option even in patients with underlying malignant arrhythmias. <Learning objective: Long-term management of Heartware biventricular assist devices (BIVADs) using low-molecular-weight heparin is possible. This treatment strategy can serve as an alternative to oral anticoagulants in a select group of patients. This case report also suggests that BIVADs can potential","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Dec","modification":"2025-04-04T12:41:23.82Z","creation":"2019-10-30T08:14:32Z"},"accession":"S-EPMC6283705","cross_references":{"pubmed":["30546687"],"doi":["10.1016/j.jccase.2016.08.002"]}}